v3.26.1
Basis of Presentation and Summary of Significant Accounting Policies - Segment Profit or Loss (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance        
Total revenues and income $ 63,693 $ 47,627 $ 115,415 $ 92,960
Share-based compensation     (24,249) (17,833)
Other segment items:        
Amortization of intangibles (8,097) (8,258) (16,194) (16,515)
Interest expense (1,748) (1,153) (3,495) (2,020)
Net income (loss) 8,591 8,444 25,959 (27,772)
Other expense items, net 30,000 16,500 42,300 77,000
Castle Creek Investment        
Other segment items:        
Recognized research and development expense       44,300
Development and Licensing of Biopharmaceutical Assets        
Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance        
Total revenues and income 63,693 47,627 115,415 92,960
Share-based compensation (13,653) (9,997) (24,249) (17,833)
Other segment items:        
Amortization of intangibles (8,097) (8,258) (16,194) (16,515)
Depreciation of property and equipment (118) (264) (237) (777)
Interest income 7,298 1,621 13,953 3,392
Interest expense (1,748) (1,153) (3,495) (2,020)
Other 1,133 (24,729) (50,030) (96,811)
Net income (loss) $ 48,508 $ 4,847 $ 35,163 $ (37,604)